---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-21-001784"
form_type: "8-K"
ticker: "AXIM"
cik: "0001514946"
company_name: "AXIM BIOTECHNOLOGIES, INC."
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:33:24.960365+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AXIM Biotech signs binding term sheet to acquire FDA-cleared dry eye tests, paying 7M shares

## Summary
- AXIM to acquire two FDA-cleared dry eye diagnostic tests from Advanced Tear Diagnostics for 7M restricted shares.
- Tests include 10-minute lactoferrin assay and ocular IgE test; commercial launch targeted for early 2022.
- Dry eye disease affects ~20M in US; global DED diagnostics market projected at $9.8B by 2030.
- Binding term sheet in effect; definitive agreement and closing expected by October 1, 2021.

## SEC filing metadata
- accession: 0001096906-21-001784
- form_type: 8-K
- ticker: AXIM
- cik: 0001514946
- company_name: AXIM BIOTECHNOLOGIES, INC.
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514946/000109690621001784/0001096906-21-001784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514946/000109690621001784/axim-20210802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-21-001784
- JSON: https://secwatch.observer/filing/0001096906-21-001784.json
- Plain text: https://secwatch.observer/filing/0001096906-21-001784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.